LianBio Announces Clinical Supply Agreement with AstraZeneca in China
Thursday, July 13, 2023
LianBio announced a clinical supply agreement with AstraZeneca in China.
The agreement aims to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor developed by LianBio and BridgeBio, in combination with AstraZeneca's osimertinib, an epidermal growth factor receptor (EGFR) inhibitor.
LianBio and BridgeBio have a strategic collaboration for the clinical development and commercialisation of BBP-398 in combination with various agents in solid tumours, including non-small cell lung cancer, colourectal cancer, and pancreatic cancer. This collaboration covers mainland China and other Asian markets.
BBP-398 is a SHP2 inhibitor designed to target difficult-to-treat cancers. SHP2 is a protein-tyrosine phosphatase that plays a role in regulating cellular proliferation and survival through its connections with growth factor, cytokine, and integrin signalling, as well as the downstream RAS/ERK MAPK pathway.
In China, a significant percentage of NSCLC patients have EGFR mutations. While EGFR inhibitors are commonly used in their treatment, many patients eventually develop resistance to these therapies. BBP-398, as a differentiated SHP2 inhibitor, has the potential to restore sensitivity to EGFR inhibitors when used in combination therapy.
